分子生物学
IVD分子诊断
细胞培养与分析
蛋白研究
细胞因子
重组蛋白
抗体
高通量测序建库
病原检测UCF系列
生物医药
工具酶
抑制剂激活剂与常用试剂
仪器
耗材

PD-1 signalling defines and protects leukaemic stem cells from T cell receptor-induced cell death in T cell acute lymphoblastic leukaemia

Xu Xi, Zhang Wenwen, Xuan Li, Yu Yanhui, Zheng Wen, Tao Fang, Nemechek Jacqelyn, He Chong, Ma Weiwei, Han Xue, Xie Siyu, Zhao Minyi, Wang Jian, Qu Yuhua, Liu Qifa, Perry John M., Jiang Linjia, Zhao Meng

Journal:NATURE CELL BIOLOGY

IF:21.3

DOI:10.1038/s41556-022-01050-3

PMID:36624186

Published:2023-01-09

research field:分子生物学癌症研究免疫学

Abstract

T cell acute lymphoblastic leukaemia (T-ALL) is an aggressive malignancy with poor prognosis, but a decisive marker and effective treatment for leukaemia stem cells (LSCs) remain unclear. Here, using lineage tracing, limiting dilution assays and in vivo live imaging approaches, we identify rare inhibitory receptor programmed cell death 1 (PD-1)-expressing cells that reside at the apex of leukaemia hierarchy for initiation and relapse in T-ALL. Ablation of PD-1-expressing cells, deletion of PD-1 in T-ALL cells or blockade of PD-1 or PD-1 ligand 1 significantly eradicated LSCs and suppressed disease progression. Combination therapy using PD-1 blockade and chemotherapy substantially extended the survival of mice engrafted with mouse or human T-ALL cells. Mechanistically, PD-1 + LSCs had high NOTCH1–MYC activity for disease initiation. Furthermore, PD-1 signalling maintained quiescence and protected LSCs against T cell receptor-signal-induced apoptosis. Overall, our data highlight the hierarchy of leukaemia by identifying PD-1 + LSCs and provide a therapeutic approach for the elimination of LSCs through PD-1 blockade in T-ALL.

本文使用的Yeasen产品

购物车
客服
转染试用